Eli Lilly released results from two late-stage trials showing that people who switched from higher-dose Wegovy or Zepbound to lower doses of Lilly's Foundayo pill or lower-dose Zepbound kept nearly all their weight loss over one year. The trials suggest the lower doses work well enough to maintain results when people switch from stronger versions.

• •Two late-stage trials tested switching from higher-dose incretin therapy to lower doses
• •Patients switched to Foundayo pill or lower-dose Zepbound maintained weight loss over one year
• •Results came from Eli Lilly press releases, not yet peer-reviewed

Novo Nordisk cut prices on Wegovy and Ozempic in India and saw sales jump 40% in April. The price cuts made the weight-loss and diabetes drugs more affordable in that market.

• •Novo Nordisk India sales rose 40% in April
• •Growth followed price cuts on Wegovy and Ozempic
• •Price cuts applied in the India market

Novo Nordisk's CEO says the pill form of Wegovy (semaglutide) is selling faster than ever in the United States. The company sees strong demand for the oral version of its weight-loss drug.

• •Novo's CEO called the US launch of oral Wegovy a record-breaking start
• •Oral Wegovy uses semaglutide, the same drug as the Wegovy shot
• •Novo reports strong early US demand for the pill version

Novo Nordisk says its pill version of Wegovy (semaglutide) is on track to become a blockbuster drug, even as the weight-loss market fills up with competitors. The company is competing with other GLP-1 drugs like tirzepatide (Mounjaro) from Eli Lilly.

• •Novo Nordisk says its Wegovy pill is on track to become a blockbuster
• •The pill is an oral version of semaglutide
• •Novo faces competition from Lilly's tirzepatide (Mounjaro) in GLP-1 market

Novo Nordisk's oral version of Wegovy (semaglutide pill) is being prescribed more often to new patients. The shift shows doctors are choosing the pill form instead of just the injection.

• •Novo's oral Wegovy is gaining share in new prescriptions
• •Doctors are choosing the pill form over the shot for some new patients

Novo Nordisk's stock outlook improved after its oral version of Wegovy (semaglutide) showed strong results. The company raised its financial forecast for 2026 based on this pill drug's success.

• •Novo Nordisk raised its 2026 outlook after oral Wegovy showed strong results
• •Oral Wegovy is a pill form of semaglutide

Novo Nordisk reported better-than-expected first-quarter profits, driven by strong sales of the pill form of Wegovy (a weight-loss drug). The company's oral semaglutide product is selling faster than Wall Street had predicted.

• •Novo Nordisk beat first-quarter profit estimates
• •Oral Wegovy demand drove the earnings beat
• •Pill semaglutide sales topped Wall Street expectations

Novo Nordisk's oral version of Wegovy (semaglutide pill) sold twice as much as Wall Street expected in the first quarter of 2026. The strong sales helped lift the company's stock price.

• •Oral Wegovy sales doubled Wall Street estimates in Q1 2026
• •Novo Nordisk stock recovered on the results

Starting July 2026, Medicare will cover Wegovy (semaglutide) for eligible patients with just a $50 monthly copay. This is a major expansion that makes the weight-loss drug affordable for millions of older Americans.

• •CMS will cover Wegovy for eligible Medicare patients starting July 2026
• •Eligible patients will pay a $50 monthly copay
• •Wegovy is Novo Nordisk's semaglutide weight-loss drug

Novo Nordisk's stock rose 1.74% after U.S. demand for Wegovy (semaglutide) reached over one million patients. The milestone shows growing prescription numbers for the weight-loss drug in America.

• •Novo Nordisk stock rose 1.74%
• •US Wegovy patient count topped one million
• •Wegovy is Novo's semaglutide weight-loss drug

Investment bank BMO raised its price target for Novo Nordisk after the pill version of Wegovy (semaglutide) showed growing customer interest. The bank's forecast suggests the oral drug could help boost the company's sales and stock value.

• •BMO raised its price target on Novo Nordisk
• •The bank cited growing interest in the Wegovy pill
• •Wegovy pill is the oral version of semaglutide

Novo Nordisk's Rybelsus (the pill form of semaglutide, sold as Wegovy for weight loss) is performing better than the company expected. Novo is being cautious about celebrating the results publicly.

• •Novo Nordisk's oral semaglutide is beating the company's own expectations
• •Novo is staying cautious in public about the results

Novo Nordisk reported strong first-quarter growth driven by Wegovy, its weight-loss injection. The company is speeding up development of an oral (pill) version of the same drug for the U.S. market.

• •Novo Nordisk reported strong Q1 growth driven by Wegovy
• •Company is speeding up work on an oral version of the drug
• •Oral push is aimed at the US obesity market

Novo Nordisk's CEO says the company found the right price for Wegovy, the pill version of its weight-loss drug. The pill brought in $355 million in sales in one quarter after it started selling.

• •Novo CEO says Wegovy pill is priced in a 'sweet spot'
• •Wegovy pill brought in $355 million in its debut quarter

Novo Nordisk's stock rose after demand for Wegovy pills (the oral version of semaglutide, a weight-loss drug) exceeded what investors expected. Strong pill sales suggest more patients are choosing this form over the injectable version.

• •Novo Nordisk stock rose on strong Wegovy pill demand
• •Oral semaglutide demand beat investor estimates

Novo Nordisk reported better-than-expected earnings and raised its outlook for the rest of the year, driven by strong sales of Wegovy, the pill version of its weight-loss drug semaglutide. The company is seeing more demand than it predicted for the oral form of the medication.

• •Novo Nordisk beat earnings estimates
• •Novo raised its full-year guidance
• •Wegovy pill demand drove the surge

Novo Nordisk's Wegovy pill (oral semaglutide) reached 1 million patients and generated $355 million in sales, exceeding company expectations. The oral form has become a major revenue driver alongside the injectable version.

• •Novo's Wegovy pill (oral semaglutide) reached 1 million patients
• •Oral Wegovy generated $355 million in sales
• •Sales beat Novo's own expectations

Novo Nordisk's first-quarter 2026 results got a boost from a reversal of the 340B drug discount program and a record launch of Wegovy (semaglutide) in pill form in the U.S. The 340B program change likely means the company will collect more money from government health programs.

• •Novo Nordisk Q1 2026 results got a boost from a 340B reversal
• •Wegovy pill had a record US launch
• •340B change likely means more revenue from government health programs

Novo Nordisk's US launch of Wegovy pills (the oral form of semaglutide) is boosting the company's business. The pill version gives patients another way to take the weight-loss drug besides injections.

• •Novo Nordisk launched Wegovy pills in the US
• •The pill is an oral form of semaglutide
• •Launch is helping Novo's business

Novo Nordisk's Wegovy weight-loss pill sales are climbing, boosting the company's financial outlook. Wegovy is an injected drug that helps people lose weight by reducing appetite.

• •Novo Nordisk says Wegovy sales are rising
• •Higher Wegovy sales are lifting the company's outlook

Novo Nordisk beat Wall Street expectations in the first quarter of 2026, driven by strong sales of Wegovy pill (the oral form of semaglutide, a weight-loss drug). The company's performance shows growing demand for the easier-to-take pill version instead of injections.

• •Novo Nordisk beat Wall Street expectations in Q1 2026
• •Wegovy pill (oral semaglutide) drove the sales beat
• •Demand is shifting toward the pill form over injections

• •Novo Nordisk stock jumped on stronger-than-expected Wegovy pill sales
• •News framed as part of obesity drug fight with Eli Lilly

Novo Nordisk reported better-than-expected earnings in the first quarter and raised its profit forecast, driven by strong sales of Wegovy (a weight-loss injection). The company said demand for the drug remains very high.

• •Novo Nordisk beat Q1 earnings estimates
• •Company raised its profit forecast
• •Strong Wegovy demand drove the results

Novo Nordisk reported that its oral version of Wegovy (semaglutide pill) performed better than expected in the first quarter. The company is encouraged by the strong sales of the pill form of its weight-loss drug.

• •Novo Nordisk says oral Wegovy beat expectations in Q1
• •Oral Wegovy is the pill form of semaglutide
• •Company points to strong sales of the pill version

Novo Nordisk beat earnings expectations in the first quarter, driven by strong sales of Wegovy pill form (the oral version of its weight-loss drug). The pill version is gaining traction with patients and doctors.

• •Novo Nordisk beat Q1 earnings expectations
• •Strong sales of the Wegovy pill drove the beat
• •Oral Wegovy is gaining use with patients and doctors

Novo Nordisk raised its sales forecast for the year after the pill version of Wegovy (semaglutide) had a very strong start. The company called the launch a record-breaking one.

• •Novo Nordisk raised its annual sales outlook
• •Oral Wegovy (semaglutide) had a record launch
• •Pill version of the weight-loss drug is driving the upgrade

Novo Nordisk expects its pill version of Wegovy (a weight-loss drug) to help offset declining sales of the injection form. The company believes the oral option will attract new patients and boost overall revenue.

• •Novo Nordisk expects oral Wegovy to help offset declining injection sales
• •Company sees the pill drawing in new weight-loss patients

Novo Nordisk beat sales forecasts in the first quarter, helped by the launch of the pill version of Wegovy (a weight-loss drug). The company's stock price stayed steady after the news.

• •Novo Nordisk beat Q1 sales forecasts
• •Launch of Wegovy pill helped drive the sales beat
• •Novo Nordisk stock held steady after the report

Novo Nordisk plans to sell the pill version of Wegovy (semaglutide) in new countries during the first half of this year. The company is expanding beyond the injection form it already sells.

• •Novo plans to launch Wegovy tablets in new markets in the first half of the year
• •The pill uses semaglutide, the same drug as the Wegovy injection